Free shipping on orders from 160 €from 160 € 3-vial Retatrutide 30 mg pack at 150 € See the packs
ORDER

Benefits of KLOW: what studies have actually measured

Everywhere you read that KLOW repairs tendons, skin, and the intestines. These claims come from studies conducted on each component, mostly in animals. Here's what has been measured, on which model, and what remains to be proven.

KLOW 80 mg – €89.90

At a glance

No benefits of KLOW have been demonstrated, as the mixture has not been studied. However, data exists for each of its four peptides. The level of evidence varies considerably: strong for the cosmetic use of GHK-Cu on the skin, preliminary for the other three.

The evidence, peptide by peptide

PeptideArea studiedMain modelLevel of evidence
GHK-CuCollagen, skin, healingCells, animal, cosmetics applied to the skinThe most documented, especially in terms of topical application
BPC-157Tendons, muscles, digestive mucosaRat, then three small human studiesPreliminary: 30 people in total, with no control group
TB-500Cell migration, wound healingAnimal; human trials of full-length thymosin beta-4Preliminary, and not on the TB-500 fragment
KPVIntestinal and skin inflammationCells and micePreclinical only

Tendons, muscles and recovery

This is the most frequently cited argument. In rats, BPC-157 accelerated the healing of injured tendons and muscles (review by Gwyer et al., 2019). However, a recent systematic review found only three human studies, with a total of 30 participants, all of low methodological quality. Its authors conclude that BPC-157 should only be used within controlled clinical trials.

Thymosin beta-4, on the other hand, accelerated wound closure in rats (Malinda et al., 1999). Human trials focused on the whole protein, applied topically to wounds, and not on the TB-500 sold in powder form. The FDA states that it has not identified any human exposure data for this fragment.

Skin and collagen

GHK-Cu occurs naturally in the body, and its levels decline with age. It stimulates collagen production in skin cells and is used in cosmetics under the name Copper Tripeptide-1 (review by Pickart and Margolina, 2018). This data primarily concerns products applied to the skin. For comparison with other forms, see GHK-Cu by injection or cream and GHK-Cu and hair.

Inflammation and the intestines

KPV is a three-amino-acid fragment of alpha-MSH. In mice with colitis, it reduced intestinal inflammation after being absorbed by the PepT1 transporter (Dalmasso et al., 2008). Its presence is what distinguishes KLOW from GLOW. The FDA states that it has not identified any human exposure data for KPV.

And the synergy of the four peptides?

The word "synergy" appears on most sales pages. It describes a hypothesis, not a result. To demonstrate it, one would have to compare the mixture to each peptide individually, and no one has published such a comparison. It is also unknown whether the four peptides remain stable together over time once in solution. If your research focuses on a single mechanism, an isolated peptide provides a result that is easier to interpret: see KLOW, GLOW or Wolverine.

KLOW 80 mg – €89.90
One lyophilized vial, i.e., €1.12/mg. Batch MP-777K801 quantified by Janoshik: 97.33 mg measured, 80 mg stated. Shipping from the European Union in 2 to 5 business days; delivery €10, free from €160.
KLOW 80 mg – €89.90

Frequently asked questions

What are the benefits of KLOW?

No benefits have been demonstrated for the mixture, due to a lack of testing. Its components are being studied for collagen and skin (GHK-Cu), tendons and muscles (BPC-157), cell migration (TB-500) and inflammation (KPV).

Does KLOW help with muscle recovery?

There is no evidence to support this. The data on tendons and muscles come mainly from rat studies on BPC-157 and thymosin beta-4.

Is KLOW good for the skin?

GHK-Cu is well-documented in cosmetics, especially for topical application. These results cannot be extrapolated to the KLOW mixture.

Is the synergy of KLOW proven?

No. No published study has compared the mixture to each of its peptides taken alone.

Are there any scientific opinions on BPC-157 in humans?

A systematic review identified three studies, with 30 participants, of low methodological quality. It concluded that controlled trials are necessary.

Sources: Pickart L., Margolina A., Int J Mol Sci 2018; Gwyer D. et al., Cell Tissue Res 2019; Malinda K.M. et al., J Invest Dermatol 1999; Dalmasso G. et al., Gastroenterology 2008; systematic review, Acta Orthop Belg (PubMed 42885452); FDA, List of Compounded Substances (April 2026). MyPeptide products are intended exclusively for scientific laboratory research.

FRENDEITESPTNLPLSV
Back to top